Lurbinectedin is a novel anticancer drug that has been recently approved for the treatment of small cell lung cancer (SCLC). According to the sources provided, Lurbinectedin has shown promising results in clinical trials and has been found to be an effective treatment option for SCLC.

One study published in the Journal of Clinical Oncology [3] evaluated the efficacy of Lurbinectedin in patients with relapsed SCLC. The study showed that Lurbinectedin significantly improved progression-free survival (PFS) compared to topotecan, which is a standard second-line treatment for SCLC. The study concluded that Lurbinectedin is a viable option for the treatment of relapsed SCLC.

Another study published in the Journal of Medical Economics [2] evaluated the cost-effectiveness of Lurbinectedin as a second-line treatment for SCLC. The study found that Lurbinectedin is a cost-effective treatment option compared to other second-line treatments for SCLC.

Additionally, the Drug Patent Watch website [1] provides information on the patents and exclusivity of Lurbinectedin, which indicates that the drug has been approved by the FDA for the treatment of SCLC.

In conclusion, Lurbinectedin has been found to be an effective treatment option for SCLC, with clinical trials showing improved PFS compared to standard treatments. The drug has also been found to be cost-effective as a second-line treatment for SCLC. Therefore, Lurbinectedin is a promising treatment option for patients with SCLC who have relapsed or are refractory to standard treatments.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.targetedonc.com/view/lurbinectedin-is-cost-effective-as-a-second-line-treatment-in-sclc
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/